DAXXIFY^TM (DaxibotulinumtoxinA-Lanm) for Injection, for Intramuscular Use

Area of Science:

• Dermatology
• Neurology
• Aesthetics

Background:

• Daxxify (daxibotulinumtoxinA-lanm) is a novel botulinum toxin Type A formulation.
• It utilizes a unique peptide excipient for enhanced neuronal membrane binding and potentially longer duration of action.
• Glabellar lines (GLs) result from corrugator and/or procerus muscle activity.

Purpose of the Study:

• To evaluate the efficacy and safety of daxibotulinumtoxinA for Injection (DAXI) in adults with moderate to severe glabellar lines.
• To establish DAXI as a treatment option for temporary improvement in the appearance of glabellar lines.

Main Methods:

• Two randomized, double-blind, placebo-controlled Phase 3 trials (SAKURA 1 and SAKURA 2) were conducted.
• Primary endpoint: composite clinical outcome of ≥2-point improvement in GL severity at week 4.
• An open-label, multi-cycle study (SAKURA 3) assessed long-term outcomes in a larger population.

Main Results:

• Treatment success rates in SAKURA 1 and SAKURA 2 were 74% for DAXI versus 0% for placebo at week 4.
• SAKURA 3 showed sustained efficacy with treatment success proportions of 73.2%, 77.7%, and 79.6% across three cycles.
• The recommended dose is 40 units administered via five intramuscular injections.

Conclusions:

• DaxibotulinumtoxinA for Injection demonstrated high efficacy in treating moderate to severe glabellar lines.
• The novel formulation may contribute to its effectiveness and duration.
• DAXI offers a new therapeutic option for glabellar line aesthetic improvement.